X
Xsira Pharmaceuticals
Biotechnology company that uses proprietary technology for the discovery and development of drugs
About Xsira Pharmaceuticals
Originally founded as Norak Biosciences, Inc. in 1999, the company rebranded to Xsira Pharmaceuticals, Inc. in 2005. As a biopharmaceutical entity, its primary focus was on the discovery and development of drugs centered around G protein-coupled receptors (GPCRs). The company's core asset was its proprietary Transfluor technology, a cell-based screening method licensed from Duke University. This platform was designed to measure GPCR activity, a key process in regulating the body's response to drugs for conditions like asthma, heart problems, and pain.
The Transfluor technology offered a universal, high-content screening assay applicable to both known and orphan GPCRs, which are receptors whose natural ligands are yet to be identified. By identifying small molecule compounds that modulate these receptors, the company aimed to develop pharmaceutical candidates for significant medical needs and large markets. The technology was particularly focused on researching compounds with better desensitization profiles to address drug tolerance and resistance. In early 2005, a significant strategic shift occurred when Xsira sold its Transfluor drug technology to Molecular Devices. Following this sale, the company licensed the rights to adenosine, a clinical-stage analgesic for post-surgical pain, indicating a move away from early-stage discovery towards later-stage drug development. Shortly after these strategic changes and the rebranding in 2005, the company significantly downsized its workforce, retaining only a few management personnel.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Feb 2002 | $13M | $52M | Intersouth Partners · Aurora Funds · Noro-Moseley Partners · Koch Enterprises | ↗ |
| SPINOUT✓Other financing | Jan 1999 | $0 | — | Duke University | — |
Growth signals
Latest recorded traffic for Xsira Pharmaceuticals is 1.1K monthly website visits, up 64.2% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Xsira Pharmaceuticals in the Morrisville ecosystem
The Xsira Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Intersouth Partners
Aurora Funds
Noro-Moseley Partners
Koch Enterprises
Mitsui Global Investment
Alexandria Venture Investments
Other known investors1 additional known investor
Duke University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xsira Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xsira Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








